Samsung Biologics Estimates US$100 Million Strike Loss as Unions Press Demands

Why It Matters

The strike threatens Samsung Biologics’ ability to meet client demand and could delay a planned capacity expansion, potentially shifting business to rival contract manufacturers. It also signals escalating labour pressure within South Korea’s tech and pharma conglomerates, which may affect investor confidence.

Key Takeaways

• Strike costs Samsung Biologics roughly $130 million so far
• Union demands 9.3% wage rise plus profit‑share bonus
• Half of 2,861 staff have been on strike since April 28
• Potential sixth plant review may be delayed by labour dispute

Pulse Analysis

Samsung Biologics, a leading contract drug manufacturer for global giants such as Pfizer and Novartis, reported a $130 million loss from a strike that began on April 28. The work stoppage, involving about 1,400 employees, has forced the company to curtail production at its five existing plants, reducing its ability to deliver biologics on schedule. While management has offered a 6.2% pay increase, the union is pushing for a 9.3% raise and a bonus tied to operating profit, highlighting the widening gap between labour expectations and corporate cost‑control measures.

The immediate impact extends beyond the balance sheet. Clients that rely on Samsung Biologics for low‑cost, on‑time delivery may look to European or U.S. contract manufacturers if the dispute drags on, eroding market share in a highly competitive sector. Moreover, the strike coincides with a strategic review of a sixth production facility that could boost capacity by several hundred thousand litres. Delays in that project could hamper the firm’s ability to capture new, high‑margin biologics contracts, especially as rivals vie for the same pipeline of antibody therapies.

The broader context is a wave of labour unrest across the Samsung Group, with Samsung Electronics workers planning an 18‑day strike later in May. Such coordinated pressure could amplify supply‑chain disruptions, push up semiconductor and drug‑manufacturing costs, and prompt investors to reassess exposure to South Korean conglomerates. For Samsung Biologics, reaching a settlement quickly is critical to preserving client confidence, maintaining its expansion timeline, and sustaining its position in the global contract manufacturing market.